Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Joseph-Wild-Strasse 20
81829 München, Germany
Tel: 49-89-451519010
Celgene is a global biopharmaceutical company founded at 1986 in New Jersey, USA. The company explores, develops and markets innovative medicines mainly for the treatment of cancer and diseases of the immune system. Celgene is represented in Germany since 2006 by Celgene GmbH in Munich-Riem. In cooperation with selected medical institutions worldwide, Celgene has currently more than 200 clinical studies. These innovative materials used in its pipeline show convincing results in the treatment of diseases of the hematopoietic system. These include multiple myeloma called myelodysplastic syndromes, chronic lymphatic leukemia and non-Hodgkin’s lymphoma. Moreover, promising results are already present in the treatment of solid tumors of the ovary, pancreas and prostate.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country,…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
See our Cookie Privacy Policy Here
